Michael Heltzen insider trades
Open-market stock purchases and sales by Michael Heltzen, Chief Executive Officer at Exozymes Inc, from SEC Form 4 filings since Nov 15, 2024.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -9%.
Recent trades
No open-market trades in the last 12 months.